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Abstract 
A growing amount of evidence demonstrates the role 
of non-coding RNAs (ncRNA) in the 
etiopathogenesis of cancer. ncRNA are the product 
of the transcription of genes which are not further 
translated into proteins, thus they exert their 
functions as they are or  more frequently  after post-
transcriptional modifications. In the last decades, 
several different classes of ncRNA had been 
described, both long (lncRNA) and short (sncRNA). 
The former are molecules usually longer than 200 
nucleotides (nt), while the latter usually include 
species of a few tens of nucleotides in length, 
although exceptions are present (for example, 
circRNA span a length of 100-1600nt; snoRNA are 
60-300nt). Y RNA belong to the sncRNA family and 
are in the range of ca. 80-120nt. Here we summarize 
the current knowledge about Y RNA biology, their 
role in normal cellular homeostasis, and their 
expression variations in human cancers. 
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Discovery, evolutionary 
conservation and structure 
The first discovery of Y RNA (Lerner et al. 1981) 
has been made by immunopurification with auto-
antibodies in patients affected by the autoimmune 
diseases systemic lupus erythematosus (SLE) and 
subsequently confirmed in (i) primary Sjogren 
syndrome, (ii) subacute cutaneous lupus 
erythematosus, (iii) neonatal lupus erythematosus, 
(iv) ANA-negative lupus erythematosus, and (v) 
systemic lupus erythematosus-like disease. These 
diseases are characterized by having as autoantigen 
targets, among the others, the soluble 
ribonucleoproteins (RNP) (also known as SSA or 
TROVE2 - TROVE domain family, member 2) 
(Deutscher et al. 1988; Ben-Chetrit et al. 1989) and 
(small RNA-binding exonuclease protection factor - 
also known as La) (Chambers et al. 1988). Y RNA 
are small non-coding RNAs that were originally 
identified as the RNA component of RO60 and SSB 
in these patients (Lerner et al. 1981; Hendrick et al. 
1981). Y RNA, like other small RNAs, are 
transcribed by RNA Polymerase III (Pol III) 
(Hendrick et al. 1981; Wolin and Steitz 1983). After 
transcription, they may either remain inside the 
nucleus or be exported in the cytoplasm (Kowalski 
and Krude 2015). They were originally termed as 'Y' 
RNA to distinguish their cytoplasmic localization 
from that of the nuclear 'U' RNA (Lerner et al. 1981). 
There are four known Y RNA members in humans, 
named hY1 (length: 112 nucleotides, nt), hY3 
(101nt), hY4 (93nt) and hY5 (83nt) RNA; the 
presence of hY2 RNA was later confuted, as it was 
found that it is a degradation product of hY1. 
According to ENSEMBL 75, there are also an 
additional 52 transcripts which are pseudogenes 
based on the 4 human Y RNA, and a further 966 
hYRNA pseudogenes (Perreault et al. 2005), with 
878 predicted transcripts, that make up the Y RNA 
category. In the most common use, hY1-5 are the 
names of the RNAs, while the HGNC approved gene 
symbol for the four genes are RNY1-5, respectively 
(i.e. , , and ).  
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Figure 1: structure of a generic human Y RNA. For the structure of specific genes, please see for example (Köhn et al. 2013); 
note that the loop domain is the less conserved both in length and structure, among all studied organisms and among the four 
human RNAs. Image taken from the Rfam database release 9.1 (http://rfam.xfam.org/family/RF00019) and partially modified 
(picture rotation; indication of domains). Nucleotide coloring indicates sequence conservation between the members of this 
family. 
 
Y RNA have two recognized functions: repressors of 
RO60 and other Ro proteins, and initiation factors 
for DNA replication (Christov et al. 2006; Zhang et 
al. 2011; Hall et al. 2013). Y RNA are conserved 
molecules, and confirmed (true Y RNA) or putative 
(stem-bulge RNAs, sbRNA (Boria et al. 2010)) 
members of this family are found in mammals, birds, 
amphibians, fishes, worms, insects, tunicates and 
even bacteria (Mosig et al. 2007; Perreault et al. 
2007; Boria et al. 2010; Duarte Junior et al. 2015, 
2019). However, in some lower organisms such as 
Caenorhabditis elegans (CeY RNA), Branchiostoma 
floridae (BfY RNA) and Deinococcus radiodurans 
(DrY RNA) the sequence similarity to vertebrate Y 
RNA is only partial and does not include the upper 
stem domain (Gardiner et al. 2009); moreover, their 
function is not essential in them, since mutant 
organisms with missing Y RNA are viable. To date, 
only plants and fungi do not have any candidate Y 
RNA or sbRNA, thus the evolution of these 
molecules is still a debated topic in eukaryotes. 
The stem-loop organization of Y RNA is conserved 
as well, and it is schematically reported in Figure 1. 
Four specific regions can be identified. (i) A poly-
uridine tail that is important for SSB binding and for 
Y RNA stabilization (target of exonucleases); 
moreover, some authors suggest that, at least hY1 
and hY3, potentially contain a variety of 3' ends, 
with the most abundant species being at positions -5 
and -4 relative to the previously mapped 3' ends 
(Shukla and Parker 2017). (ii) A lower stem domain, 
which is the binding site of RO60 and is important 
for nuclear export; this region is frequently flanked 
by a bulged region that is essential for RO60 binding 
and separates the lower stem from (iii) an upper stem 
domain, which is important for the initiation of DNA 
replication. Finally, (iv) a loop domain, which is the 
most variable portion of the Y RNA. In particular, 
the loop domain length and sequence are the most 
discriminating parameters among the four human Y 
RNA, the longest loop being that of hY1 (65 nt) and 
the shortest that of hY5 (31 nt). Also the three-
dimensional folded structure of the loops differ 
significantly among the four hY RNA: it is likely 
very flexible (Teunissen 2000) and fulfills different 
tasks such as modulation of chromatin association,  
protein binding site (such as those reported in Table 
1) (Fabini et al. 2001; Fouraux et al. 2002; Belisova 
et al. 2005; Hogg and Collins 2007; Gallois-
Montbrun et al. 2008; Sim et al. 2012; Köhn et al. 
2013, 2015; Shukla and Parker 2017; Donovan et al. 
2017) and site of cleavage for the formation of 
YsRNA (Y RNA-derived small RNAs, stretches of 
22-36 nucleotides that are produced in apoptotic 
cells - see the specific section below) (van Gelder et 
al. 1994; Teunissen 2000; Kowalski and Krude 
2015). It is expected that Y RNA contemporarily 
bind at least two proteins, one of which is a core 
protein bound on the stem domain (such as RO60) 
and another on the loop domain; indeed, experiments 
using gel filtration show that Y RNP range in size 
from 150 to 550 kDa (see (Köhn et al. 2013) and 
references therein). All human Y RNA genes map 
inside the region 7q36.1 (Maraia et al. 1994; Maraia 
1996) and, in particular, RNY3 is on the opposing 
DNA strand from the gene RNY1 (Wolin and Steitz 
1983); interestingly, despite their high homology, 
these two RNAs do not cross-hybridize (Wolin and 
Steitz 1983). This clustering of Y RNA coding genes 
on chromosomes has been described also in other 
vertebrates (O'Brien et al. 1993; Farris et al. 1996; 
Mosig et al. 2007).  
Role of Y RNA in RO60 function 
Ro ribonucleoproteins (Ro RNP) are implicated in 
RNA processing and quality control (Hogg and 
Collins 2007; Sim and Wolin 2011), as well as in 
intracellular transport, bringing other Y RNA 
binding proteins to their specific targets (Belisova et 
al. 2005). It has been recently proposed that an 
evolutionarily conserved function of non-coding 
RNAs (ncRNA), including Y RNA, might be the 
assembly and function of RNP complexes; in this 
case, these molecules could act as scaffolding factors 
necessary to form functional RNP (Täuber et al. 
2019). 
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Protein (HGNC) Synonyms Interacting Y RNA Domain involved Function 
 CEM15 1, 3, 4, 5 unknown unknown 
 NEB1 1, 3 loop histone pre-mRNA processing 
 EXOSC11 (1), (3) polyU tail Y RNA stabilization 
 DIS3L1 1, 3 polyU tail Y RNA degradation and turnover 
 PMSCL2 1, 3, 4, 5 polyU tail Y RNA trimming, stabilization 
 HNRPK 1, 3 loop unknown 
 C20ORF183 (1), 3 loop nuclear Export of RO60 and Y3 
 nucleolin, C23 1, 3 loop unknown 
 DAN 1, 3, 4, 5 polyU tail Y RNA trimming, stabilization 
 hnRNP I, PTB 1, 3 loop unknown 
 RoBP1, FIR (1), (3), 5 unknown unknown 
 PRCA1, RNS4 1, (3), 4, 5 loop cell cycle arrest and apoptosis 
 La, LARP3 1, 3, 4, 5 polyU tail nuclear localization, protection of Y RNA 3' ends 
 PAPD5 1, 3, 4, 5 polyU tail Y RNA oligoadenylation, degradation 
 PCH7 1, (3) polyU tail Y RNA degradation and turnover 
 TROVE2, Ro60, SSA 1, 3, 4, 5 lower stem stabilization, nuclear export, RNA quality control 
Table 1 - Y RNA binding proteins. Numbers inside parentheses indicate unconfirmed data or minor effects. Protein names 
(column 1) are those approved by the HUGO (Human Genome Organisation) Gene Nomenclature Committee (HGNC). Proteins 
are listed in alphabetical order according to data in column 1. 
 
RO60 is a 60kDa ring-shaped RNA-binding protein 
(Stein et al. 2005) important in the response to 
environmental stress, such as exposure to UV 
radiation or heat, in both animal cells and bacteria. It 
is highly conserved (Sim and Wolin 2011; Wolin et 
al. 2013), able to bind aberrant non-coding RNAs 
such as mis-folded 5S rRNA or U2 snRNA (O'Brien 
and Wolin 1994; Chen et al. 2003) and possibly 
acting as a cellular stress sensors (reviewed in 
(Kowalski and Krude 2015; Boccitto and Wolin 
2019)).  
Structural and biochemical studies have shown that 
the binding affinity of Y RNA for RO60 is higher 
than that of mis-folded RNA, suggesting that Y RNA 
might act as a RO60 repressor (Stein et al. 2005; 
Fuchs et al. 2006), although some evidence support 
the hypothesis that these molecules (or, at least, hY5) 
might also enhance the recognition of mis-folded 
ncRNA (Hogg and Collins 2007).  
It has been suggested that the interaction of Y RNA 
with nucleolin (NCL), polypyrimidine tract-binding 
proteins (PTB) and Z-DNA binding protein 1 
(ZBP1) (Köhn et al. 2013) might modulate the 
subcellular localisation of RO60 (Sim and Wolin 
2011).  
Indeed, RO60 can move between nucleus and 
cytoplasm, in a Y RNA-dependent way (Sim et al. 
2009; Sim and Wolin 2011) and, in turn, RO60 
protects them from degradation and allows their 
accumulation in several species (Chen and Wolin 
2004). Consequently, some authors suggest a model 
where Y RNA and bound RO60 can dissociate under 
certain conditions, so that RO60 can act in cellular 
recovery by salvaging mis-folded RNAs. In this 
context, it is possible to hypothesize that other RNA-
binding proteins could complex Y RNA in a similar 
fashion, to fulfill additional tasks, such as mRNA 
regulation (Köhn et al. 2013).  
Role of Y RNA in DNA replication 
Y RNA functions during DNA replication seem 
quite distinct from those related to RO60 functions 
(Langley et al. 2010). Indeed, Langley and 
collaborators showed that immunodepletion of 
RO60 and SSB RNP from human cytosolic extracts 
does not inhibit DNA replication in human cell 
nuclei (Langley et al. 2010). Similarly, deletion of 
RO60 and SSB binding sites on the lower stem 
domain of vertebrate Y RNA does not inhibit the 
DNA replication activity of the mutant Y RNA 
(Christov et al. 2006; Gardiner et al. 2009) indicating 
that the role of Y RNA in DNA replication is 
uncoupled from Ro RNP binding. Instead, RNA 
interference (RNAi)-mediated depletion of either 
hY1, hY3, or hY4 RNA in cell cultures eliminates or 
reduces DNA replication in these cells (Christov et 
al. 2006, 2008; Krude et al. 2009; Collart et al. 2011), 
and DNA replication is restored back by artificial 
reintroduction of any of them; the only exception 
being for hY5, which is consequently thought to be 
refractory to RNAi. Similarly, functional 
inactivation of Y RNA (sbRNA in worms (Boria et 
al. 2010)) via microinjection of antisense 
morpholino oligonucleotides (MOs) in embryos, is 
sufficient to impair DNA replication in Xenopus 
laevis, Danio rerio and Caenorhabditis elegans, 
where this treatment impairs DNA replication and 
causes cell cycle arrest and embryonic lethality 
(Collart et al. 2011; Kowalski et al. 2015). In this 
context, it is not surprising that Y RNA are over-
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expressed in some human solid tumors (Christov et 
al. 2008) (see also the specific sections below).  
Y RNA function in DNA replication is fulfilled by 
the upper stem domain (Gardiner et al. 2009; Wang 
et al. 2014; Kowalski et al. 2015) which is important 
also for the recognition of specific chromatin 
domains and DNA replication initiation proteins 
(Zhang et al. 2011; Collart et al. 2011). Interestingly, 
however, this interaction does not include replication 
fork proteins (Zhang et al. 2011) suggesting that the 
interaction is restricted to the DNA replication 
initiation complex (Kheir and Krude 2017). Indeed, 
Y RNA localize inside nuclei in G1, before DNA 
replication, and they are displaced upon DNA 
replication initiation (Zhang et al. 2011). To date, 
there is no certainty about their role in this process, 
and only hypotheses may be drawn (Kowalski and 
Krude 2015). Interestingly, although all Y RNA 
localize inside the nucleus, only hY1, hY3 and hY4 
co-localize with each other on early-replicating 
euchromatin; instead, hY5 is prevalently localized in 
nucleoli (Zhang et al. 2011). This different behavior 
of hY5 is recurrent also in some of the tumors 
described below. This localization is controlled, in 
all Y RNA, by the loop domain. Differently, the 
nuclear export of Y RNA is controlled by the lower 
stem domain and is dependent on the small GTPase 
Ran (Rutjes et al. 2001).  
Y RNA derivatives 
Intracellular localization of Y RNA is dependent on 
cellular stress (Chen and Wolin 2004); specifically, 
both RO60 and Y RNA are up-regulated and 
accumulate inside the nucleus following UV 
irradiation, starvation, heat stress, γ-irradiation, and 
desiccation (Sim et al. 2009, 2012; Boccitto and 
Wolin 2019). However, it has been noted that this 
phenomenon could also be just a byproduct of the 
inhibition of RanGTP gradient under stress 
conditions (Köhn et al. 2013). The RNA component 
of Ro RNP is partly degraded during apoptosis and 
generates the so called Y RNA-derived small RNAs 
(YsRNA), such as miR-1975 and miR-1979. 
However, is not required for the production of these 
YsRNA (Nicolas et al. 2012; Langenberger et al. 
2013) and indeed, after their identification as 
byproducts of Y RNA degradation, miR-1975 and 
miR-1979 were removed from miRBase 
(http://www.mirbase.org/), the primary database for 
micro RNAs. These shorter fragments are 
specifically, abundantly and rapidly generated from 
all four Y RNA during apoptosis, in a caspase-
dependent manner (Rutjes et al. 1999), but it is not 
yet clear if they have any causal role in these 
phenomena, or are just a product of apoptosis-
mediated cellular changes (Rutjes et al. 1999; Meiri 
et al. 2010). These Y RNA degradation products 
remain bound to the RO60 protein and, in part, also 
to the SSB protein (Rutjes et al. 1999). This suggests 
that the rapid degradation of these molecules might 
occur at an early step during the systemic 
deactivation of the dying cell. Despite the role of 
these molecules is currently unknown, YsRNA have 
been identified both in healthy tissues (Nicolas et al. 
2012; Yamazaki et al. 2014) and in precursor B cells 
of acute lymphoblastic leukaemia patients (Schotte 
et al. 2009) as well as in solid tumors (Meiri et al. 
2010); for these reasons, they are under investigation 
as possible biomarkers in cancer and/or other 
conditions (Meiri et al. 2010; Nicolas et al. 2012; 
Dhahbi 2014; Vojtech et al. 2014; Ikoma et al. 2018). 
Indeed, these fragments - especially those derived 
from hY4 - are particularly abundant in plasma, 
serum (Dhahbi et al. 2013; Yeri et al. 2017; Umu et 
al. 2018) and other biofluids (Vojtech et al. 2014; 
Godoy et al. 2018), where they circulate as part of a 
complex with a mass between 100 and 300 kDa but 
not included in exosomes or microvesicles (Dhahbi 
et al. 2013). Some authors suggest that, beyond what 
described before, Y RNA and their derivatives might 
also fulfill a signaling (Dhahbi et al. 2013) or a gene 
regulation (Van Balkom et al. 2015) function; 
actually, a role in gene regulation has also been 
described for the maturation of histone mRNA 
through hY3 and its derivative, hY3** (a smaller 
60nt-long Y RNA) (Köhn et al. 2015; Köhn and 
Hüttelmaier 2016). Noteworthy, these fragments are 
not confined inside cells, but can be found also in 
blood circulation, with a specific enrichment of hY4 
derivatives (Dhahbi et al. 2013), and inside 
extracellular vesicles (EV) for hY5 derivatives 
(Chakrabortty et al. 2015). More detailed 
descriptions of these fragments can be found in the 
following specific sections on human tumors.  
Y RNA and human cancer 
The role of Y RNA in DNA replication (and, 
consequently, in the regulation of cell cycle) sets the 
basis to hypothesize their possible role in cancer 
etiology. Indeed, there are reports showing that Y 
RNA are significantly up-regulated (4- to 13-fold for 
hY4 and hY1, respectively) in human cancer tissues 
(carcinomas and adenocarcinomas of the lung, 
kidney, bladder, prostate, , and ) compared to normal 
tissues (Christov et al. 2008), and are also required 
for the proliferation of cancer cells, since their RNA 
interference (RNAi)-mediated degradation results in 
a significant cytostatic (but not cytotoxic) effect in 
cell lines, probably by inducing a significant 
inhibition of chromosomal DNA replication in 
cultured human cells (Christov et al. 2008). 
Interestingly, hY5 seems under control of an 
independent mechanism since its cellular amount is 
frequently different from that of the other three Y 
RNA, although over-expressed as well in at least 
some tumors (Christov et al. 2008).  
As said, it has been reported in 2008 that hY1 and 
hY3 are highly over-expressed in (Christov et al. 
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2008). Instead, in 2017 Tolkach and collaborators 
reported that all Y RNA are down-regulated in BC 
(Tolkach et al. 2017), with the low abundance of 
hY1, hY3 and hY4 typical of muscle-invasive 
bladder cancer (MIBC) compared to non-muscle-
invasive bladder cancer (NMIBC) and that low 
amount of hY1, hY3 and hY4 also correlates with 
lymph node metastases and advanced grade. No 
correlation was found with age or gender. Further 
studies are needed to assess with certainty if, in 
bladder cancer, Y RNA are indeed down-regulated.  
Dhabi and collaborators detected inside the serum 
and plasma the presence of RNA fragments, 
including YsRNA (Dhahbi et al. 2013). Using this 
approach, they later verified if their abundance can 
be related to (Dhahbi et al. 2014). They found a 
major population of 30-33nt long fragments mostly 
derived from Y RNA 5' end, and a minor population 
of 25-29nt long fragments almost exclusively 
derived from their 3' end. Interestingly, some 
fragments increase while other decrease their 
amount, in a specific pattern. This result is in good 
agreement with a previous study describing an 
enrichment of 3'-end fragments - derived from 
human hY5 - detected in MCF 7 (mammary 
adenocarcinoma) cells (Nicolas et al. 2012). More 
recently (Guo et al. 2018), another study on (TNBC) 
showed similar results for RNY1, RNY5 and, above 
all, RNY4 expression, while another group (Tosar et 
al. 2015) found fragments of 31-33nt greatly and 
significantly enriched in the extracellular space of 
cultured breast cancer cells, suggesting that this 
fragments are specifically excreted by these cells.  
As for (the most common tumor of the brain), to 
date, only one manuscript was published, dealing 
with Y RNA (Wei et al. 2017). In glioma cells, all 
extracellular fractions, especially non-vesicular 
RNPs, are highly enriched in specific Y RNA 
fragments ca. 32nt in length, especially belonging to 
hY1, hY4 and hY5.  
Martinez and collaborators reported that in 
(HNSCC), Y RNA-derived small RNAs are 
significantly deregulated in the sera of patients 
(Martinez et al. 2015). These patients have, among 
the others, an enrichment of 30-33nt-long fragments 
deriving from Y RNA degradation, and these 
fragments proportion either increases or decreases 
significantly for specific RNA species, suggesting a 
remodeling of the small non-coding RNA networks 
in HNSCC. Recently, Dhahbi and coworkers 
analyzed Y RNA fragments in (OSCC), a form of 
HNSCC and the most common type of head and neck 
cancer (Dhahbi et al. 2019). Also in this case, the 
authors found that multiple 5' Y RNA fragments 
displayed significant differential expression levels in 
circulation and/or tumor tissue, as compared to their 
control counterparts.  
Bernatsky and collaborators demonstrated that many 
cancer types, and hematologic malignancies in 
particular, are substantially increased in patients 
affected by systemic lupus erythematosus 
(Bernatsky et al. 2013). Chakrabortty and coworkers 
(Chakrabortty et al. 2015) demonstrated that primary 
cell cultures are sensitive to apoptosis induction 
either by treatment with K562 cells EV, or by the 
ectopic over-expression of 31nt-processed fragments 
of hY5. Instead, this treatment is inefficient on 
cancer cells, suggesting that this might be a way for 
cancer cells to create a favorable microenvironment 
(Chakrabortty et al. 2015). More recently, a study on 
(CLL) (Haderk et al. 2017) revealed that (i) hY4 is 
highly enriched in exosomes; (ii) it is sufficient to 
activate cytokine release in monocytes and trigger in 
these cells the activation of Toll-like receptor 7 ( ), 
(iii) the pharmacologic inhibition of endosomal TLR 
attenuates CLL development in vivo; (iv) in CLL 
patients, the PD-L1 pathway is activated, allowing 
the tumor cells to escape the immune response.  
It has been shown (Nientiedt et al. 2018) that in 
(ccRCC) patients, the expression of RNY3 and 
RNY4 is significantly increased and that the 
expression levels of RNY4 alone is inversely 
correlated with ccRCC stage and the presence of 
lymph node metastases.  
In (ADC) and (SQCC) patients, Li and collaborators 
(Li et al. 2018) showed that 5' hY4-derived 
fragments have a significantly higher expression in 
plasma EV compared to controls, while they are 
down-regulated inside cancer; moreover, over-
expressing hY4 inhibits the proliferation of lung 
cancer cell line A549, suggesting for hY4 fragments 
a role of tumor suppressors in this pathology. These 
results show evident differences from those reported 
before (Christov et al. 2008), thus a further 
validation of either data is advisable.  
The analysis of ncRNA content of EV of the cell line 
MML-1 (Lunavat et al. 2015) demonstrated that 
there is a specific signature of Y RNA present in EV, 
with hY1, hY4 and hY5 significantly more abundant 
in EV than inside melanoma cells, while hY3 
amount is similar inside EV and MML-1 cells. These 
data were partly validated by the recent work of Sole 
and collaborators (Sole et al. 2019) who found an 
enrichment of hY4 and, to a lesser extent, of hY1 and 
hY3, but only in patients with stage 0 disease.  
Quantification of Y RNA in samples (Tolkach et al. 
2018) revealed a down-regulation of these molecules 
two to fourfold, compared to normal tissue. The 
authors also found that higher RNY5 expression is 
associated with poor prognosis, measured as 
biochemical recurrence-free survival. Interestingly, 
these results are in contrast with those found for 
bladder cancer (see above), further supporting the 
use of Y RNA as a valid biomarker for cancer 
identification. Also for prostate cancer, these data 
contrast with those reported before (Christov et al. 
2008) thus a more in depth analysis is required to 
validate either results.  
Y RNA in cell cycle progression and cancer Piergentili R 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2020; 24(10) 384 
 
References 
Belisova A, Semrad K, Mayer O, Kocian G, Waigmann E, 
Schroeder R, Steiner G. RNA chaperone activity of protein 
components of human Ro RNPs. RNA. 2005 
Jul;11(7):1084-94 
Ben-Chetrit E, Gandy BJ, Tan EM, Sullivan KF. Isolation 
and characterization of a cDNA clone encoding the 60-kD 
component of the human SS-A/Ro ribonucleoprotein 
autoantigen. J Clin Invest. 1989 Apr;83(4):1284-92 
Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, 
Boivin JF, Petri M, Zoma A, Manzi S, Urowitz MB, Gladman 
D, Fortin PR, Ginzler E, Yelin E, Bae SC, Wallace DJ, 
Edworthy S, Jacobsen S, Gordon C, Dooley MA, Peschken 
CA, Hanly JG, Alarcón GS, Nived O, Ruiz-Irastorza G, 
Isenberg D, Rahman A, Witte T, Aranow C, Kamen DL, 
Steinsson K, Askanase A, Barr S, Criswell LA, Sturfelt G, 
Patel NM, Senécal JL, Zummer M, Pope JE, Ensworth S, 
El-Gabalawy H, McCarthy T, Dreyer L, Sibley J, St Pierre Y, 
Clarke AE. Cancer risk in systemic lupus: an updated 
international multi-centre cohort study. J Autoimmun. 2013 
May;42:130-5 
Boccitto M, Wolin SL. Ro60 and Y RNAs: structure, 
functions, and roles in autoimmunity. Crit Rev Biochem Mol 
Biol. 2019 Apr;54(2):133-152 
Boria I, Gruber AR, Tanzer A, Bernhart SH, Lorenz R, 
Mueller MM, Hofacker IL,  Stadler PF. Nematode sbRNAs: 
homologs of vertebrate Y RNAs J Mol Evol  2010 
Apr;70(4):346-58 
Chakrabortty SK, Prakash A, Nechooshtan G, Hearn S, 
Gingeras TR. Extracellular vesicle-mediated transfer of 
processed and functional RNY5 RNA RNA  2015 
Nov;21(11):1966-79 
Chambers JC, Kenan D, Martin BJ, Keene JD. Genomic 
structure and amino acid sequence domains of the human 
La autoantigen J Biol Chem 1988 Dec 5;263(34):18043-51 
Chen X, Smith JD, Shi H, Yang DD, Flavell RA, Wolin SL. 
The Ro autoantigen binds misfolded U2 small nuclear RNAs 
and assists mammalian cell survival after UV irradiation 
Curr Biol 2003 Dec 16;13(24):2206-11 
Chen X, Wolin SL. The Ro 60 kDa autoantigen: insights into 
cellular function and role in autoimmunity J Mol Med (Berl) 
2004 Apr;82(4):232-9 
Christov CP, Trivier E, Krude T. Noncoding human Y RNAs 
are overexpressed in tumours and required for cell 
proliferation Br J Cancer  2008 Mar 11;98(5):981-8 
Collart C, Christov CP, Smith JC, Krude T. The midblastula 
transition defines the onset of Y RNA-dependent DNA 
replication in Xenopus laevis Mol Cell Biol 2011 
Sep;31(18):3857-70 
Deutscher SL, Harley JB, Keene JD. Molecular analysis of 
the 60-kDa human Ro ribonucleoprotein Proc Natl Acad Sci 
U S A 1988 Dec;85(24):9479-83 
Dhahbi J, Nunez Lopez YO, Schneider A, Victoria B, 
Saccon T, Bharat K, McClatchey T, Atamna H, Scierski W, 
Golusinski P, Golusinski W, Masternak MM. Profiling of 
tRNA Halves and YRNA Fragments in Serum and Tissue 
From Oral Squamous Cell Carcinoma Patients Identify Key 
Role of 5' tRNA-Val-CAC-2-1 Half Front Oncol  2019 Sep 
26;9:959 
Dhahbi JM. Circulating small noncoding RNAs as 
biomarkers of aging Ageing Res Rev 2014 Sep;17:86-98 
Dhahbi JM, Spindler SR, Atamna H, Boffelli D, Martin DI. 
Deep Sequencing of Serum Small RNAs Identifies Patterns 
of 5' tRNA Half and YRNA Fragment Expression Associated 
with Breast Cancer Biomark Cancer 2014 Dec 8;6:37-47 
Donovan J, Rath S, Kolet-Mandrikov D, Korennykh A. Rapid 
RNase L-driven arrest of protein synthesis in the dsRNA 
response without degradation of translation machinery RNA  
2017 Nov;23(11):1660-1671 
Duarte Junior FF, de Lima Neto QA, Rando Fdos S, de 
Freitas DV, Pattaro Júnior JR, Polizelli LG, Munhoz RE, 
Seixas FA, Fernandez MA. Identification and molecular 
structure analysis of a new noncoding RNA, a sbRNA 
homolog, in the silkworm Bombyx mori genome Mol Biosyst 
2015 Mar;11(3):801-8 
Fabini G, Raijmakers R, Hayer S, Fouraux MA, Pruijn GJ, 
Steiner G. The heterogeneous nuclear ribonucleoproteins I 
and K interact with a subset of the ro ribonucleoprotein-
associated Y RNAs in vitro and in vivo J Biol Chem 2001 
Jun 8;276(23):20711-8 
Farris AD, Gross JK, Hanas JS, Harley JB. Genes for 
murine Y1 and Y3 Ro RNAs have class 3 RNA polymerase 
III promoter structures and are unlinked on mouse 
chromosome 6 Gene  1996 Sep 26;174(1):35-42 
Fouraux MA, Bouvet P, Verkaart S, van Venrooij WJ, Pruijn 
GJ. Nucleolin associates with a subset of the human Ro 
ribonucleoprotein complexes J Mol Biol 2002 Jul 
12;320(3):475-88 
Fuchs G, Stein AJ, Fu C, Reinisch KM, Wolin SL. Structural 
and biochemical basis for misfolded RNA recognition by the 
Ro autoantigen Nat Struct Mol Biol  2006 Nov;13(11):1002-
9 
Gallois-Montbrun S, Holmes RK, Swanson CM, Fernández-
Ocaña M, Byers HL, Ward MA, Malim MH. Comparison of 
cellular ribonucleoprotein complexes associated with the 
APOBEC3F and APOBEC3G antiviral proteins J Virol 2008 
Jun;82(11):5636-42 
Gardiner TJ, Christov CP, Langley AR, Krude T. A 
conserved motif of vertebrate Y RNAs essential for 
chromosomal DNA replication RNA 2009 Jul;15(7):1375-85 
Godoy PM, Bhakta NR, Barczak AJ, Cakmak H, Fisher S, 
MacKenzie TC, Patel T, Price RW, Smith JF, Woodruff PG, 
Erle DJ. Large Differences in Small RNA Composition 
Between Human Biofluids Cell Rep 2018 Oct 
30;25(5):1346-1358 
Guo Y, Yu H, Wang J, Sheng Q, Zhao S, Zhao YY, 
Lehmann BD. The Landscape of Small Non-Coding RNAs 
in Triple-Negative Breast Cancer Genes (Basel) 2018 Jan 
10;9(1) 
Haderk F, Schulz R, Iskar M, Cid LL, Worst T, Willmund KV, 
Schulz A, Warnken U, Seiler J, Benner A, Nessling M, Zenz 
T, Göbel M, Dürig J, Diederichs S, Paggetti J, Moussay E, 
Stilgenbauer S, Zapatka M, Lichter P, Seiffert M. Tumor-
derived exosomes modulate PD-L1 expression  
in monocytes Sci Immunol  2017  Jul 28;2(13) 
Hall AE, Turnbull C, Dalmay T. Y RNAs: recent 
developments Biomol Concepts 2013 Apr;4(2):103-10 
Hendrick JP, Wolin SL, Rinke J, Lerner MR, Steitz JA. Ro 
small cytoplasmic ribonucleoproteins are a subclass of La 
ribonucleoproteins: further characterization of the Ro and 
La small ribonucleoproteins from uninfected mammalian 
cells Mol Cell Biol  1981 Dec;1(12):1138-49 
Hogg JR, Collins K. Human Y5 RNA specializes a Ro 
ribonucleoprotein for 5S ribosomal RNA quality control 
Genes Dev  2007 Dec 1;21(23):3067-72 
Y RNA in cell cycle progression and cancer Piergentili R 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2020; 24(10) 385 
 
Ikoma M, Gantt S, Casper C, Ogata Y, Zhang Q, Basom R, 
Dyen MR, Rose TM, Barcy S. KSHV oral shedding and 
plasma viremia result in significant changes in the 
extracellular tumorigenic miRNA expression profile in 
individuals infected with the malaria parasite PLoS One  
2018 Feb 9;13(2):e0192659 
Köhn M, Pazaitis N, Hüttelmaier S. Why YRNAs? About 
Versatile RNAs and Their Functions Biomolecules 2013 
Feb 8;3(1):143-56 
Kheir E, Krude T. Non-coding Y RNAs associate with early 
replicating euchromatin in concordance with the origin 
recognition complex J Cell Sci  2017  Apr 1;130(7):1239-
1250 
Kowalski MP, Krude T. Functional roles of non-coding Y 
RNAs Int J Biochem Cell Biol 2015 Sep;66:20-9 
Krude T, Christov CP, Hyrien O, Marheineke K. Y RNA 
functions at the initiation step of mammalian chromosomal 
DNA replication J Cell Sci  2009 Aug 15;122(Pt 16):2836-
45 
Langenberger D, akir MV, Hoffmann S, Stadler PF. Dicer-
processed small RNAs:  rules and exceptions J Exp Zool B 
Mol Dev Evol 2013 Jan;320(1):35-46 
Langley AR, Chambers H, Christov CP, Krude T. 
Ribonucleoprotein particles containing non-coding Y RNAs, 
Ro60, La and nucleolin are not required for Y RNA function 
in DNA replication PLoS One  2010 Oct 27;5(10):e13673 
Lerner MR, Boyle JA, Hardin JA, Steitz JA. Two novel 
classes of small ribonucleoproteins detected by antibodies 
associated with lupus erythematosus Science 1981 Jan 
23;211(4480):400-2 
Li C, Qin F, Hu F, Xu H, Sun G, Han G, Wang T, Guo M. 
Characterization and selective incorporation of small non-
coding RNAs in non-small cell lung cancer extracellular 
vesicles Cell Biosci  2018 Jan 10;8:2 
Lunavat TR, Cheng L, Kim DK, Bhadury J, Jang SC, Lässer 
C, Sharples RA, López  MD, Nilsson J, Gho YS, Hill AF, 
Lötvall J. Small RNA deep sequencing discriminates 
subsets of extracellular vesicles released by melanoma 
cells--Evidence of unique microRNA cargos RNA Biol  
2015;12(8):810-23 
Maraia R, Sakulich AL, Brinkmann E, Green ED. Gene 
encoding human Ro-associated autoantigen Y5 RNA 
Nucleic Acids Res  1996 Sep 15;24(18):3552-9 
Maraia RJ, Sasaki-Tozawa N, Driscoll CT, Green ED, 
Darlington GJ. The human Y4 small cytoplasmic RNA gene 
is controlled by upstream elements and resides on 
chromosome 7 with all other hY scRNA genes Nucleic Acids 
Res  1994 Aug 11;22(15):3045-52 
Meiri E, Levy A, Benjamin H, Ben-David M, Cohen L, Dov 
A, Dromi N, Elyakim E,  Yerushalmi N, Zion O, Lithwick-
Yanai G, Sitbon E. Discovery of microRNAs and other small 
RNAs in solid tumors Nucleic Acids Res  2010 
Oct;38(18):6234-46 
Mosig A, Guofeng M, Stadler BM, Stadler PF. Evolution of 
the vertebrate Y RNA  cluster Theory Biosci  2007 
Aug;126(1):9-14 
Nicolas FE, Hall AE, Csorba T, Turnbull C, Dalmay T. 
Biogenesis of Y RNA-derived small RNAs is independent of 
the microRNA pathway FEBS Lett  2012 Apr 
24;586(8):1226-30 
Nientiedt M, Schmidt D, Kristiansen G, Müller SC, Ellinger 
J. YRNA Expression  Profiles are Altered in Clear Cell Renal 
Cell Carcinoma Eur Urol Focus  2018 Mar;4(2):260-266 
O'Brien CA, Wolin SL. A possible role for the 60-kD Ro 
autoantigen in a discard pathway for defective 5S rRNA 
precursors Genes Dev 1994 Dec 1;8(23):2891-903 
Perreault J, Perreault JP, Boire G. Ro-associated Y RNAs 
in metazoans: evolution and diversification Mol Biol Evol 
2007 Aug;24(8):1678-89 
Rutjes SA, Lund E, van der Heijden A, Grimm C, van 
Venrooij WJ, Pruijn GJ. Identification of a novel cis-acting 
RNA element involved in nuclear export of hY RNAs RNA 
2001 May;7(5):741-52 
Rutjes SA, van der Heijden A, Utz PJ, van Venrooij WJ, 
Pruijn GJ. Rapid nucleolytic degradation of the small 
cytoplasmic Y RNAs during apoptosis J Biol Chem 1999 
Aug 27;274(35):24799-807 
Schotte D, Chau JC, Sylvester G, Liu G, Chen C, van der 
Velden VH, Broekhuis MJ, Peters TC, Pieters R, den Boer 
ML. Identification of new microRNA genes and aberrant 
microRNA profiles in childhood acute lymphoblastic 
leukemia Leukemia  2009 Feb;23(2):313-22 
Shukla S, Parker R. PARN Modulates Y RNA Stability and 
Its 3'-End Formation Mol Cell Biol 2017 Sep 26;37(20) 
Sim S, Weinberg DE, Fuchs G, Choi K, Chung J, Wolin SL. 
The subcellular distribution of an RNA quality control 
protein, the Ro autoantigen, is regulated by noncoding Y 
RNA binding Mol Biol Cell 2009 Mar;20(5):1555-64 
Sim S, Wolin SL. Emerging roles for the Ro 60-kDa 
autoantigen in noncoding RNA metabolism Wiley Interdiscip 
Rev RNA 2011 Sep-Oct;2(5):686-99 
Sim S, Yao J, Weinberg DE, Niessen S, Yates JR 3rd, Wolin 
SL. The zipcode-binding protein ZBP1 influences the 
subcellular location of the Ro 60-kDa autoantigen and the 
noncoding Y3 RNA RNA 2012 Jan;18(1):100-10 
Sole C, Arnaiz E, Manterola L, Otaegui D, Lawrie CH. The 
circulating transcriptome as a source of cancer liquid biopsy 
biomarkers Semin Cancer Biol   2019 Oct;58:100-108 
Stein AJ, Fuchs G, Fu C, Wolin SL, Reinisch KM. Structural 
insights into RNA quality control: the Ro autoantigen binds 
misfolded RNAs via its central cavity Cell  2005 May 
20;121(4):529-539 
Täuber H, Hüttelmaier S, Köhn M. POLIII-derived non-
coding RNAs acting as scaffolds and decoys J Mol Cell Biol 
2019 Oct 25;11(10):880-885 
Teunissen SW, Kruithof MJ, Farris AD, Harley JB, Venrooij 
WJ, Pruijn GJ. Conserved features of Y RNAs: a 
comparison of experimentally derived secondary structures 
Nucleic Acids Res 2000 Jan 15;28(2):610-9 
Tolkach Y, Niehoff EM, Stahl AF, Zhao C, Kristiansen G, 
Müller SC, Ellinger J. YRNA expression in prostate cancer 
patients: diagnostic and prognostic implications World J 
Urol  2018 Jul;36(7):1073-1078 
Tolkach Y, Stahl AF, Niehoff EM, Zhao C, Kristiansen G, 
Müller SC, Ellinger J. YRNA expression predicts survival in 
bladder cancer patients BMC Cancer  2017 Nov 
10;17(1):749 
Tosar JP, Gámbaro F, Sanguinetti J, Bonilla B, Witwer KW, 
Cayota A. Assessment of small RNA sorting into different 
extracellular fractions revealed by high-throughput 
sequencing of breast cell lines Nucleic Acids Res  2015 Jun 
23;43(11):5601-16 
Umu SU, Langseth H, Bucher-Johannessen C, Fromm B, 
Keller A, Meese E, Lauritzen M, Leithaug M, Lyle R, Rounge 
TB. A comprehensive profile of circulating RNAs in human 
serum RNA Biol 2018 Feb 1;15(2):242-250 
Y RNA in cell cycle progression and cancer Piergentili R 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2020; 24(10) 386 
 
Victoria Martinez B, Dhahbi JM, Nunez Lopez YO, 
Lamperska K, Golusinski P, Luczewski L, Kolenda T, 
Atamna H, Spindler SR, Golusinski W, Masternak MM. 
Circulating small non-coding RNA signature in head and 
neck squamous cell carcinoma Oncotarget  2015 Aug 
7;6(22):19246-63 
Vojtech L, Woo S, Hughes S, Levy C, Ballweber L, 
Sauteraud RP, Strobl J, Westerberg K, Gottardo R, Tewari 
M, Hladik F. Exosomes in human semen carry a distinctive 
repertoire of small non-coding RNAs with potential 
regulatory functions Nucleic Acids Res  2014 
Jun;42(11):7290-304 
Wang I, Kowalski MP, Langley AR, Rodriguez R, 
Balasubramanian S, Hsu ST, Krude T. Nucleotide 
contributions to the structural integrity and DNA replication 
initiation activity of noncoding y RNA Biochemistry  2014 
Sep 23;53(37):5848-63 
Wei Z, Batagov AO, Schinelli S, Wang J, Wang Y, El Fatimy 
R, Rabinovsky R, Balaj L, Chen CC, Hochberg F, Carter B, 
Breakefield XO, Krichevsky AM. Coding and noncoding 
landscape of extracellular RNA released by human glioma 
stem cells Nat Commun  2017 Oct 26;8(1):1145 
Wolin SL, Belair C, Boccitto M, Chen X, Sim S, Taylor DW, 
Wang HW. Non-coding Y RNAs as tethers and gates: 
Insights from bacteria RNA Biol  2013 Oct;10(10):1602-8 
Wolin SL, Steitz JA. Genes for two small cytoplasmic Ro 
RNAs are adjacent and appear to be single-copy in the 
human genome Cell  1983 Mar;32(3):735-44 
Yamazaki F, Kim HH, Lau P, Hwang CK, Iuvone PM, Klein 
D, Clokie SJ. pY RNA1-s2: a highly retina-enriched small 
RNA that selectively binds to Matrin 3 (Matr3) PLoS One  
2014 Feb 18;9(2):e88217 
Yeri A, Courtright A, Reiman R, Carlson E, Beecroft T, 
Janss A, Siniard A, Richholt R, Balak C, Rozowsky J, 
Kitchen R, Hutchins E, Winarta J, McCoy R, Anastasi M, 
Kim S, Huentelman M, Van Keuren-Jensen K. Total 
Extracellular Small RNA Profiles from Plasma, Saliva, and 
Urine of Healthy Subjects Sci Rep  2017 Mar 17;7:44061 
Zhang AT, Langley AR, Christov CP, Kheir E, Shafee T, 
Gardiner TJ, Krude T. Dynamic interaction of Y RNAs with 
chromatin and initiation proteins during human DNA 
replication J Cell Sci  2011 Jun 15;124(Pt 12):2058-69 
van Balkom BW, Eisele AS, Pegtel DM, Bervoets S, 
Verhaar MC. Quantitative and  qualitative analysis of small 
RNAs in human endothelial cells and exosomes provides 
insights into localized RNA processing, degradation and 
sorting J Extracell Vesicles  2015 May 29;4:26760 
van Gelder CW, Thijssen JP, Klaassen EC, Sturchler C, 
Krol A, van Venrooij WJ, Pruijn GJ. Common structural 
features of the Ro RNP associated hY1 and hY5 RNAs 
Nucleic Acids Res 1994 Jul 11;22(13):2498-506 
This article should be referenced as such: 
Piergentili R. Y RNA in cell cycle progression and cancer. 
Atlas Genet Cytogenet Oncol Haematol. 2020; 
24(10):379-386. 
 
